Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2022

Genmab — Juli 2022

Planlagt Fastgjort Låst Flyttet Genmab
808 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #775

    Seagen will be responsible for commercializing tisotumab vedotin and Genmab will receive royalties based on a percentage of aggregate net sales ranging from the mid-teens to the mid-twenties.

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #776

      https://ir.genmab.com/static-files/9491d368-6f92-4511-b2af-73f96aff7752 Side 130

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #777

        Aktier/åbning: Vestas igen med fremme i grøn start for C25
        https://www.proinvestor.com/investornyt/857841/aktier-abning-vestas-igen-med-fremme-i-gron-start-for-c25

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #778

          no, depends on geography Solsen

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #779

            Genmab is co-promoting Tivdak in the U.S. and will lead
            commercial operational activities in Japan. Seagen is leading commercial operational activities in the
            U.S. and will lead commercial operational activities in Europe and China. In these four markets there will
            be a 50:50 cost and profit split. In any other markets, Seagen will commercialize Tivdak and Genmab will
            receive royalties based on a percentage of aggregate net sales ranging from the mid-teens to the midtwenties. T

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #780

              so far we are only on the US

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #781

                *in

                1 Reply Last reply
                0
                • D Offline
                  D Offline
                  deleted-user
                  wrote on sidst redigeret af
                  #782

                  Fra aftalen 2017 "Each party has the option to co-promote by employing up to 40 percent of the sales effort in the other party's territories."

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #783

                    Det ligner at Genmab kun booker salget i Japan. Fik ikke læst det hele i første omgang - beklager. Genmab har sagt at Seagan skal træne deres salgsfolk i US.

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bikube
                      wrote on sidst redigeret af
                      #784

                      Over halvdelen af dagens hidtidige omsætning skete kl. 10,23, med en stigning fra 2630 til 2639, det var da noget af et hug.

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #785

                        Er det ikke uden betydning hvem der booker hvad. De deler jo i porten alligevel.

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #786

                          Jo men det var jo en del af diskussionen, hvornpr Genmab indtægtsførte salget.

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #787

                            Tror der lidt prestige i at få lov at booke salget.

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #788

                              Lidt travl ved tasterne så der skal gættes lidt - sorry.

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #789

                                Må hellere nyde solen i stedet.

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  ProinvestorNEWS
                                  wrote on sidst redigeret af
                                  #790

                                  Aktier/middag: Rockwool og Vestas bidrager på grøn dag
                                  https://www.proinvestor.com/investornyt/857874/aktier-middag-rockwool-og-vestas-bidrager-pa-gron-dag

                                  1 Reply Last reply
                                  0
                                  • D Offline
                                    D Offline
                                    deleted-user
                                    wrote on sidst redigeret af
                                    #791

                                    Enig Solsen. Tænker også der er prestige i principal-titlen og det, at bogføre nettoomsætning i stedet for netto profit, øger trods alt toplinjen mest. Så er det naturligvis også interessant, at følge investeringen i salgsapparatet og de mange personer der er nyansat. Det skal skabe afkast præcis som investeringer i RD. Jeg kalder det monitorering af Jan 🙂

                                    1 Reply Last reply
                                    0
                                    • D Offline
                                      D Offline
                                      deleted-user
                                      wrote on sidst redigeret af
                                      #792

                                      I øvrigt - en detalje. Af 2017 aftalen fremgår der 50:50 split af "costs and profits". Bliver det ikke umuliggjort, når man indblander faste royaltysatser i visse områder.... Spøjst

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #793

                                        Seagen earnings call transcript https://www.fool.com/earnings/call-transcripts/2022/07/29/seagen-inc-sgen-q2-2022-earnings-call-transcript/

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #794

                                          50:50 split er i de 4 markeder Japan, Kina Europa og US. alle andre markeder er der royalties til Genmab.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper